Abstract
Autologous chimeric antigen receptor engineered T-cell therapies are beginning to dramatically change the outlook for patients with several hematological malignancies. Yet methods to activate and expand these cells are limited, often pose challenges to automation, and have biological limitations impacting the output of the injectable dose. This study describes the development of a novel, highly flexible, soluble DNA-based T-cell activation and expansion platform which alleviates the limitations of current technologies and provides rapid T-cell activation and expansion.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / pharmacology
-
Antigen-Presenting Cells / immunology
-
Antigen-Presenting Cells / metabolism
-
CD28 Antigens / antagonists & inhibitors
-
CD28 Antigens / immunology
-
CD3 Complex / antagonists & inhibitors
-
CD3 Complex / immunology
-
Cell Proliferation
-
DNA / genetics
-
DNA / immunology*
-
Genetic Vectors / genetics
-
Humans
-
Immunophenotyping
-
Immunotherapy, Adoptive / methods
-
Lentivirus / genetics
-
Lymphocyte Activation / drug effects
-
Lymphocyte Activation / immunology*
-
Primary Cell Culture / methods
-
Receptors, Antigen, T-Cell / genetics
-
Receptors, Antigen, T-Cell / immunology
-
Receptors, Chimeric Antigen / genetics
-
Receptors, Chimeric Antigen / immunology
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology*
-
T-Lymphocytes / metabolism*
-
Transduction, Genetic
Substances
-
Antibodies, Monoclonal
-
CD28 Antigens
-
CD3 Complex
-
Receptors, Antigen, T-Cell
-
Receptors, Chimeric Antigen
-
DNA